Please upgrade your browser.
Maximum tolerated dose chemotherapy followed by metronomic chemotherapy a method using frequent low doses plus a multikinase inhibitor improved PFS and response rates in patients with metastatic renal cell carcinoma, according to the findings of a phase-2 trial.
The Use of the American Society of Anesthesiology Classification as a Prognostic Factor in Patients with Renal Cell Carcinoma
The authors analyzed whether the American Society of Anesthesiology classification could be used as a prognostic factor in renal cell carcinoma. The ASA classification could be used as a prognostic factor in renal cell carcinoma.
NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation
NEDD8 ultimate buster 1 (NUB1) is an interferon (IFN)-inducible protein that downregulates NEDD8 expression and its conjugation system. Although overexpression of NUB1 induces a growth-inhibitory effect in cells, the mechanisms underlying the anti-mitogenic actions of NUB1 in cancer cells remain uncertain. We investigated the anti-cancer effects of NUB1 in human renal cell carcinoma (RCC) cells.
I had kidney cancer in 2007, in the U.S., I got a CAT scan in 24 hours and had the surgery that saved my life within two weeks. Under the Canadian system, I would have waited at least six months for the CAT scan perhaps over a year, the cancer would have killed me long before then.
George Milton Lopeman Jr., 64, Gardner, died peacefully surrounded by family on Sunday, January 17, 2010, at Villa St. Francis Nursing Home, Olathe, after a long battle with cancer.
A growing list of noteworthy figures from the world of sports, and others, are joining Hollywood stars to support World Kidney Day, March 11, 2010.
Patients With Advanced Kidney Cancer: Switching To Metronomic Therapy Could Offer New Treatment Option
An article published Online First in The Lancet Oncology reports that a new multi-targeted "chemo-switch" drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma (RCC).
Elderly patients were more often asymptomatic than younger patients, with 7079 year olds being the least symptomatic. Incidental cases of RCC have recently become more common. Haematuria, hypersedimentation, chronic and systemic symptoms have decreased. Stage, tumour class, gender and age are correlated with symptoms.
In a randomised phase III trial, sunitinib significantly improved efficacy over interferon-alpha (IFN-alpha) as first-line therapy for metastatic renal cell carcinoma (mRCC). We report the final health-related quality of life (HRQoL) results.
|Powered by NeonCRM|